{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058675","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.231472+00:00","generated_at":"2026-06-02T09:22:12.904010+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase","bullets":["Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.","Proceeds to repurchase portion of outstanding 0.750% 2025 Notes, fund capped call transactions, and repurchase up to $50M of common stock.","Capped call transactions expected to reduce dilution upon conversion and offset cash payments in excess of principal amount.","Entered First Amendment to Credit Agreement to permit $150M share repurchase program and the proposed note offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058675","json":"https://secwatch.observer/filing/0001104659-24-058675.json","markdown":"https://secwatch.observer/filing/0001104659-24-058675.md","text":"https://secwatch.observer/filing/0001104659-24-058675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000110465924058675/0001104659-24-058675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000110465924058675/tm2413714d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:22:12.904010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1111b15f6257edcd3f60ca01b69c48e8b884f131","claim":"Pacira BioSciences, Inc. amended First TLA Amendment with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024, Pacira BioSciences, Inc. (the “Company”), JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders entered into a first amendment (the “First TLA Amendment”) to the Credit Agreement, dated as of March 31, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000110465924058675/0001104659-24-058675-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders"},{"label":"Effective","value":"2024-05-08"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}